Exact Mass: 416.2482398
Exact Mass Matches: 416.2482398
Found 500 metabolites which its exact mass value is equals to given mass value 416.2482398,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Alfentanil
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. [PubChem] D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general > N01AH - Opioid anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
Distigmine
ATC code: N07AA03
manoalide
A sesterterpenoid isolated from the marine sponge Luffariella variabilis and which has been shown to exhibit inhibitory activity towards phospholipase A2. D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
Ramipril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ramipril
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Colupox a
Colupox a is found in alcoholic beverages. Colupox a is isolated from hops. Isolated from hops. Colupox a is found in alcoholic beverages.
Colupox b
Colupox b is found in alcoholic beverages. Colupox b is isolated from hops. Isolated from hops. Colupox b is found in alcoholic beverages.
CPA(18:2(9Z,12Z)/0:0)
cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:2(9Z,12Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.
Forasartan
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
N-Eicosapentaenoyl Asparagine
N-eicosapentaenoyl asparagine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Asparagine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Asparagine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Asparagine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
9-Octadecenoic acid (9Z)-, (2-hydroxy-2-oxido-1,2-oxaphospholan-4-yl)methyl ester
C22H41O5P (416.26914660000006)
Efegatran
Elarofiban
Glutamylleucylarginine
C17H32N6O6 (416.23832120000003)
manoalide
Trecetilide
C21H37FN2O3S (416.25087840000003)
Zabicipril
Colupox a
3alpha-Angeloyloxy-18-hydroxy-ent-labd-8(17)-13dien-15,16-olide
AL 8810 Methyl ester
C25H33FO4 (416.23627500000003)
(2E,6E,9E)-11-Hydroxy-7-(hydroxymethyl)-4,11-dimethyl-4-(4-methyl-3-penten-1-yl)-8-oxo-2,6,9-cycloundecatrien-1-yl 3-methyl-2-butenoate
Distigmine
N - Nervous system > N07 - Other nervous system drugs > N07A - Parasympathomimetics > N07AA - Anticholinesterases D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D004791 - Enzyme Inhibitors
(ent-15beta)-16alpha,17-Epoxide,15-angeloyl-15-Hydroxy-16-kauren-19-oic acid|Perymenic acid
7alpha-methoxy-8,11,13-abietatriene-18-succinic acid|abiesadine G
15-alpha-angeloyloxykauren-19-oic acid 16-epoxide|15-angeloyloxy-16,17-epoxy-19-kauronoic acid
(12E,20Z,18S)-7,8-dihydro-8-hydroxyvariabilin|(12E,20Z,18S)-8-Hydroxyvariabilin|6, 7-Dihydro, 7-hydroxy-Variabilin+
(4R,5S,7S,8S,10R,11R,2S)-7-angeloyloxy-8-(alpha-methylbutyryloxy)longipin-2-en-1-one
21,24,25,26,27-pentanor-15,22-oxo-7alpha,23-dihydroxy-apotirucalla(eupha)-1-en-3-one
3,6-Di-O-acetylasterone|3beta,6alpha-Diacetoxy-5alpha-pregn-9(11)-en-20-on|3beta,6alpha-diacetoxy-5alpha-pregn-9(11)-en-20-one|diacetyl asterone
15-Angeloyl-(ent-15beta)-9, 15-Dihydroxy-16-kauren-19-oic acid|15alpha-angeloyloxy-9beta-hydroxy-ent-kaurenic acid
ent-3beta-hydroxy-14beta-tigloyloxybeyer-15-en-19-oic acid
Di-Ac-(3beta,4beta,5alpha,17(20)Z)-en-16-one-3,4-Dihydroxypregn-17(20)-en-16-one
6alpha,8alpha-dihydroxy-23-oxo-13(14),15,17-trien-16,19-olide
(5S,6E,10R)-5-beta-D-glucopyranosyloxy-3,10-dihydroxy-3,7,11-trimethyldodeca-1,5,11-triene|amarantholidoside II
11,12-Dihydroxy-19-(3-methyl-2-butanoyloxy)-8,11,13-abietatrien-7-on
3beta(H)-7beta,9alpha-diangelyloxy-1-oxolongipinane
2alpha-(2-methylbutyryloxy)-15,16-epoxylabda-7,13(16),14-trien-18-oic acid|2alpha-<2-methylbutyryloxy>-15,16-epoxylabda-7,13(16),14-trien-18-oic acid
6alpha,15(S)-dihydroxy-23-oxo-labd-8(22),13(14),17-trien-16(S),19-olide
(1S,4S,5R,7R,10R)-11,14-dihydroxyguai-3-one 11-O-beta-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-Dihydroxyguai-3-one 11-O-??-D-glucopyranoside|(1S,4S,5R,7R,10R)-11,14-dihydroxyguaian-3-one 11-O-beta-D-glucopyranoside
8alpha-23-dihydroxy-23,6alpha-epoxy-labd-13(14),15,17-trien-16,19-olide
(11S)-7-eudesmene-1beta,4beta,12-triol 1-O-beta-D-glucopyranose|iwayoside C
(5Z)-6-[5-(2-beta-D-glucopyranosyloxy-propan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol|shanyeside B
1-hydroperoxy-7,10-dihydroxybisabola-2,11-diene 7-beta-D-fucopyranoside
1-hydroperoxy-7,12-dihydroxybisabola-2,10-diene 7-beta-D-fucopyranoside
muurol-4-ene-1beta,3beta,10beta-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8R,8aS)-1,2,4a,5,6,7,8,8a-octahydro-8,8a-dihydroxy-3,8-dimethyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside
muurol-4-ene-1beta,3beta,15-triol 3-O-beta-D-glucopyranoside|rel-(2R,4aS,5R,8S,8aR)-1,2,4a,5,6,7,8,8a-octahydro-8a-hydroxy-3-(hydroxymethyl)-8-methyl-5-(1-methylethyl)naphthalen-2-yl beta-D-glucopyranoside
(3beta,5beta,14beta,16beta,20Z)-16-acetoxy-14,15-epoxy-3-hydroxy-24-norcholan-20(22)-en-21-al
(3R,3aR,5R,5aR,9S,11S,13bR)-3-[(2E)-erythro-4,5-dihydroxyhex-2-en-2-yl]-5,9-dihydroxy-3a-methyl-1,2,3,3a,4,5,5a,8,9,10,11,13b-dodecahydro-12H-6,11-methanocyclodeca[e]inden-12-one|erythro-11alpha-hydroxyneocyclocitrinol
beta-methyl-15-hydroxymethylfaurinone-9-alpha-O-beta-D-glucoside|cupressusoside
(ent-15beta)-2,3-Epoxy-2-methylbutanoyl-15-Hydroxy-16-kauren-19-oic acid|Epoxyangeloxygrandifloric acid
(3alpha,9alpha,10??)-9,10-Dihydroxy-5-longipinanone
abiesadine K|methyl 15-hydroxy-8,11,13-abietatriene-18-succinate
abiesadine H|methyl 7alpha-hydroxy-8,11,13-abietatriene-18-succinate
(5Z)-6-[5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-O-beta-D-glucopyranoside
(5S,6E,9E)-5-beta-D-glucopyranosyloxy-3,11-dihydroxy-3,7,11-trimethyldodeca-1,6,9-triene|amarantholidoside I
1beta,6beta,9alpha-trihydroxy-trans-eudesm-3-ene-6-O-beta-D-glucopyranoside
2alpha-isovaleryloxy-15,16-epoxylabda-7,13(16),14-trien-18-oic acid
1-acetyl-15,16-dimethoxy-aspidospermidine-17,21-diol|N-Acetyl-N-depropionyl-aspido-albinol
15-methoxy-8,11,13-abietatriene-18-succinic acid|abiesadine J
6alpha,11-Dihydroxy-19-(3-methyl-2-butanoyloxy)-7,9(11),13-abietatrien-12-on
2alpha,7-dihydroxykessane 2-O-beta-D-glucopyranoside
15-(3-Methyl-2-butenoyl)-(ent-15beta)-9, 15-Dihydroxy-16-kauren-19-oic acid|9beta-hydroxy-15alpha-senecioyloxy-ent-kaurenic acid|9beta-hydroxy-15alpha-senecioyloxy-ent-kaurenoic acid
Oleoyl 3-carbacyclic Phosphatidic Acid
C22H41O5P (416.26914660000006)
(Z)-(1R,3R,4R,4aS,8R,8aR)-3,4,8,8a-Tetramethyl-7-oxo-4-(2-(5-oxo-2,5-dihydrofuran-3-yl)ethyl)decahydronaphthalen-1-yl 2-methylbut-2-enoate
ALFENTANIL
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general > N01AH - Opioid anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
C25H36O5_2-Butenoic acid, 2-methyl-, (4R,6R)-3,3,7,9-tetramethyl-6-(3-methyl-1-oxobutoxy)-11-oxotricyclo[5.4.0.0~2,8~]undec-9-en-4-yl ester, (2Z)
Ala Ala Lys Gln
C17H32N6O6 (416.23832120000003)
Ala Ala Gln Lys
C17H32N6O6 (416.23832120000003)
Ala Ile Ile Thr
Ala Ile Leu Thr
Ala Ile Thr Ile
Ala Ile Thr Leu
Ala Lys Ala Gln
C17H32N6O6 (416.23832120000003)
Ala Lys Gln Ala
C17H32N6O6 (416.23832120000003)
Ala Leu Ile Thr
Ala Leu Leu Thr
Ala Leu Thr Ile
Ala Leu Thr Leu
Ala Gln Ala Lys
C17H32N6O6 (416.23832120000003)
Ala Gln Lys Ala
C17H32N6O6 (416.23832120000003)
Ala Thr Ile Ile
Ala Thr Ile Leu
Ala Thr Leu Ile
Ala Thr Leu Leu
Asp Ala Ile Val
Asp Ala Leu Val
Asp Ala Val Ile
Asp Ala Val Leu
Asp Gly Ile Ile
Asp Gly Ile Leu
Asp Gly Leu Ile
Asp Gly Leu Leu
Asp Ile Ala Val
Asp Ile Gly Ile
Asp Ile Gly Leu
Asp Ile Ile Gly
Asp Ile Leu Gly
Asp Ile Val Ala
Asp Leu Gly Ile
Asp Leu Gly Leu
Asp Leu Ile Gly
Asp Leu Leu Gly
Asp Leu Val Ala
Asp Val Ala Ile
Asp Val Ala Leu
Asp Val Ile Ala
Asp Val Leu Ala
Glu Ala Val Val
Glu Gly Ile Val
Glu Gly Leu Val
Glu Gly Val Ile
Glu Gly Val Leu
Glu Ile Gly Val
Glu Ile Val Gly
Glu Leu Gly Val
Glu Leu Val Gly
Glu Val Ala Val
Glu Val Gly Ile
Glu Val Gly Leu
Glu Val Ile Gly
Glu Val Leu Gly
Glu Val Val Ala
Gly Asp Ile Ile
Gly Asp Ile Leu
Gly Asp Leu Ile
Gly Asp Leu Leu
Gly Glu Ile Val
Gly Glu Leu Val
Gly Glu Val Ile
Gly Glu Val Leu
Gly Gly Lys Arg
C16H32N8O5 (416.24955420000003)
Gly Gly Arg Lys
C16H32N8O5 (416.24955420000003)
Gly Ile Asp Ile
Gly Ile Asp Leu
Gly Ile Glu Val
Gly Ile Ile Asp
Gly Ile Leu Asp
Gly Ile Val Glu
Gly Lys Gly Arg
C16H32N8O5 (416.24955420000003)
Gly Lys Asn Val
C17H32N6O6 (416.23832120000003)
Gly Lys Arg Gly
C16H32N8O5 (416.24955420000003)
Gly Lys Val Asn
C17H32N6O6 (416.23832120000003)
Gly Leu Asp Ile
Gly Leu Asp Leu
Gly Leu Glu Val
Gly Leu Ile Asp
Gly Leu Leu Asp
Gly Leu Val Glu
Gly Asn Lys Val
C17H32N6O6 (416.23832120000003)
Gly Asn Val Lys
C17H32N6O6 (416.23832120000003)
Gly Arg Gly Lys
C16H32N8O5 (416.24955420000003)
Gly Arg Lys Gly
C16H32N8O5 (416.24955420000003)
Gly Val Glu Ile
Gly Val Glu Leu
Gly Val Ile Glu
Gly Val Lys Asn
C17H32N6O6 (416.23832120000003)
Gly Val Leu Glu
Gly Val Asn Lys
C17H32N6O6 (416.23832120000003)
Ile Ala Asp Val
Ile Ala Ile Thr
Ile Ala Leu Thr
Ile Ala Thr Ile
Ile Ala Thr Leu
Ile Ala Val Asp
Ile Asp Ala Val
Ile Asp Gly Ile
Ile Asp Gly Leu
Ile Asp Ile Gly
Ile Asp Leu Gly
Ile Ile Ala Thr
Ile Ile Thr Ala
Ile Leu Ala Thr
Ile Leu Thr Ala
Ile Ser Val Val
Ile Thr Ala Ile
Ile Thr Ala Leu
Ile Thr Ile Ala
Ile Thr Leu Ala
Ile Val Ser Val
Ile Val Val Ser
Lys Ala Ala Gln
C17H32N6O6 (416.23832120000003)
Lys Ala Gln Ala
C17H32N6O6 (416.23832120000003)
Lys Gly Gly Arg
C16H32N8O5 (416.24955420000003)
Lys Gly Asn Val
C17H32N6O6 (416.23832120000003)
Lys Gly Arg Gly
C16H32N8O5 (416.24955420000003)
Lys Gly Val Asn
C17H32N6O6 (416.23832120000003)
Lys Asn Gly Val
C17H32N6O6 (416.23832120000003)
Lys Asn Val Gly
C17H32N6O6 (416.23832120000003)
Lys Gln Ala Ala
C17H32N6O6 (416.23832120000003)
Lys Arg Gly Gly
C16H32N8O5 (416.24955420000003)
Lys Val Gly Asn
C17H32N6O6 (416.23832120000003)
Lys Val Asn Gly
C17H32N6O6 (416.23832120000003)
Leu Ala Ile Thr
Leu Ala Leu Thr
Leu Ala Thr Ile
Leu Ala Thr Leu
Leu Ile Ala Thr
Leu Ile Thr Ala
Leu Leu Ala Thr
Leu Leu Thr Ala
Leu Ser Val Val
Leu Thr Ala Ile
Leu Thr Ala Leu
Leu Thr Ile Ala
Leu Thr Leu Ala
Leu Val Ser Val
Leu Val Val Ser
Asn Gly Lys Val
C17H32N6O6 (416.23832120000003)
Asn Gly Val Lys
C17H32N6O6 (416.23832120000003)
Asn Lys Gly Val
C17H32N6O6 (416.23832120000003)
Asn Lys Val Gly
C17H32N6O6 (416.23832120000003)
Asn Val Gly Lys
C17H32N6O6 (416.23832120000003)
Asn Val Lys Gly
C17H32N6O6 (416.23832120000003)
Gln Ala Ala Lys
C17H32N6O6 (416.23832120000003)
Gln Ala Lys Ala
C17H32N6O6 (416.23832120000003)
Gln Lys Ala Ala
C17H32N6O6 (416.23832120000003)
Arg Gly Gly Lys
C16H32N8O5 (416.24955420000003)
Arg Gly Lys Gly
C16H32N8O5 (416.24955420000003)
Arg Lys Gly Gly
C16H32N8O5 (416.24955420000003)
Ser Ile Val Val
Ser Leu Val Val
Ser Val Ile Val
Ser Val Leu Val
Ser Val Val Ile
Ser Val Val Leu
Thr Ala Ile Ile
Thr Ala Ile Leu
Thr Ala Leu Ile
Thr Ala Leu Leu
Thr Ile Ala Ile
Thr Ile Ala Leu
Thr Ile Ile Ala
Thr Ile Leu Ala
Thr Leu Ala Ile
Thr Leu Ala Leu
Thr Leu Ile Ala
Thr Leu Leu Ala
Thr Val Val Val
Val Gly Lys Asn
C17H32N6O6 (416.23832120000003)
Val Gly Asn Lys
C17H32N6O6 (416.23832120000003)
Val Ile Ser Val
Val Ile Val Ser
Val Lys Gly Asn
C17H32N6O6 (416.23832120000003)
Val Lys Asn Gly
C17H32N6O6 (416.23832120000003)
Val Leu Ser Val
Val Leu Val Ser
Val Asn Gly Lys
C17H32N6O6 (416.23832120000003)
Val Asn Lys Gly
C17H32N6O6 (416.23832120000003)
Val Ser Ile Val
Val Ser Leu Val
Val Ser Val Ile
Val Ser Val Leu
Val Thr Val Val
Val Val Ile Ser
Val Val Leu Ser
Val Val Ser Ile
Val Val Ser Leu
Val Val Thr Val
Val Val Val Thr
Forasartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
Colupox b
1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(triMethylsilyl)ethoxy)Methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone
6-AMINO-5-(2,2-DIETHOXYETHYL)-2-((4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4(3H)-ONE
6-AMINO-5-(2,2-DIETHOXYETHYL)-2-((3-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4(3H)-ONE
1-BOC-4-[4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZOYL]-PIPERAZINE
tert-butyl 4-[[2-(5-amino-3-methyl-1H-pyrazol-4-yl)-6-methoxy-phe noxy]methyl]piperidine-1-carboxylate
4-O-ACETYL-3 6-DI-O-(TERT-BUTYLDIMETHYL&
C20H40O5Si2 (416.2414150000001)
methyl 4-(10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)pentanoate
1,3,8-Triazaspiro[4.5]dec-3-en-2-one, 4-(cyclohexylamino)-1-phenyl-8-(phenylmethyl)-
C26H32N4O (416.25759819999996)
NCT-501
NCT-501 is a potent and selective theophylline-based inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), inhibits hALDH1A1 with IC50 of 40 nM, typically shows better selectivity over other ALDH isozymes and other dehydrogenases (hALDH1B1, hALDH3A1, and hALDH2, IC50 >57 μM).
tert-Butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperazine-1-carboxylate
Tonapofylline
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure[1][2].
Pregnenolone succinate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
Trecetilide
C21H37FN2O3S (416.25087840000003)
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
(2S,3aR,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
3-(6-ethoxynaphthalen-2-yl)-1-((1-methylpiperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
3,17-Bis[(trimethylsilyl)oxy]estra-1,3,5(10)-triene
2-hydroxy-3-[6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one
(2-hydroxy-2-oxo-1,2lambda5-oxaphospholan-4-yl)methyl (E)-octadec-9-enoate
C22H41O5P (416.26914660000006)
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-4-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-9-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-5-hydroxytridec-2-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-5-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-7-enoyl]oxypropyl]-trimethylazanium
vibsanin B
A vibsane diterpenoid that is (2Z,6E,10E)-cycloundeca-2,6,10-trien-1-one which is substituted at positions 2, 5, 5, 8, 9, and 9 by hydroxymethyl, methyl, 2-methylpent-2-en-5-yl, 3-methylbut-2-enoyloxy, hydroxy, and methyl groups, respectively (the 5S,8R,9R stereoisomer). It has been found to inhibit root growth in rice seedlings (IC50 0.14 mM).
(3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
Ala-Leu-Leu-Thr
A tetrapeptide composed of L-alanine, two L-leucine units, and L-threonine joined in sequence by peptide linkages.
5-Benzyl-2,3-bis(4-methoxyphenyl)-1,4-dimethylpiperazine
C27H32N2O2 (416.24636519999996)
1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)
3-[[(1,3-dimethyl-4-pyrazolyl)methyl-methylamino]methyl]-N-methyl-N-(phenylmethyl)-2-imidazo[1,2-a]pyridinecarboxamide
4-[[(3S,10R,13S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
2-[4-(2,3-Dimethylphenyl)-1-piperazinyl]-1-(8-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)ethanone
C26H32N4O (416.25759819999996)
N-[(2S,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3R,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6S)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6R)-6-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(1-oxo-2-phenylethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
16alpha,17beta-Dihydroxy-androst-4-en-3-one dipropionate
1-(9Z,12Z,15Z)-octadecatrienylglycerone 3-phosphate
A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as (9Z,12Z,15Z)-octadecatrienyl.
(3R)-3-[(2E,6E)-9-[(2S)-3,3-dimethyloxiran-2-yl]-3,7-dimethylnona-2,6-dienyl]-6-hydroxy-2,3,5-trimethyl-4-oxocyclohexa-1,5-diene-1-carboxylic acid
16alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate
1-(9Z,12Z)-octadecadienylglycerone 3-phosphate(2-)
A 1-alkylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-(9Z,12Z)-octadecadienylglycerone 3-phosphate; major species at pH 7.3.